-
公开(公告)号:US20080114887A1
公开(公告)日:2008-05-15
申请号:US11983135
申请日:2007-11-07
申请人: Mark Bryers , Elango Ganesan , Frederick Gruner , David Hass , Robert Hathaway , Ramesh Panwar , Ricardo Ramirez , Abbas Rashid , Mark Vilas , Nazar Zaidi , Yen Lee , Chau Nguyen , John Phillips , Yuhong Zhou , Gregory Spurrier , Sankar Ramanoorthi , Michael Freed
发明人: Mark Bryers , Elango Ganesan , Frederick Gruner , David Hass , Robert Hathaway , Ramesh Panwar , Ricardo Ramirez , Abbas Rashid , Mark Vilas , Nazar Zaidi , Yen Lee , Chau Nguyen , John Phillips , Yuhong Zhou , Gregory Spurrier , Sankar Ramanoorthi , Michael Freed
IPC分类号: G06F15/16
CPC分类号: H04L47/125 , H04L29/06 , H04L63/0485
摘要: A network content service apparatus includes a set of compute elements adapted to perform a set of network services; and a switching fabric coupling compute elements in said set of compute elements. The set of network services includes firewall protection, Network Address Translation, Internet Protocol forwarding, bandwidth management, Secure Sockets Layer operations, Web caching, Web switching, and virtual private networking. Code operable on the compute elements enables the network services, and the compute elements are provided on blades which further include at least one input/output port.
摘要翻译: 网络内容服务设备包括适于执行一组网络服务的一组计算元件; 以及耦合所述一组计算元件中的计算元件的交换结构。 该组网络服务包括防火墙保护,网络地址转换,互联网协议转发,带宽管理,安全套接字层操作,Web缓存,Web交换和虚拟专用网络。 在计算元件上可操作的代码实现了网络服务,并且在还包括至少一个输入/输出端口的刀片上提供计算元件。
-
公开(公告)号:US20100008851A1
公开(公告)日:2010-01-14
申请号:US12494631
申请日:2009-06-30
申请人: Nicholas C. Nicolaides , Philip M. Sass , Luigi Grasso , Wolfgang Ebel , Yuhong Zhou , Xun Zuo , Eric Routhier , Jun Yao
发明人: Nicholas C. Nicolaides , Philip M. Sass , Luigi Grasso , Wolfgang Ebel , Yuhong Zhou , Xun Zuo , Eric Routhier , Jun Yao
IPC分类号: A61K51/00 , C07K16/18 , C12N15/11 , A61K39/395 , C12N15/00 , C12N1/21 , C12N5/06 , C12P21/02 , A61K49/00
CPC分类号: C07K16/3084 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/92
摘要: Described herein are antibodies that specifically bind ganglioside GD2. Also described are nucleotides encoding such antibodies, cells expressing such antibodies, methods of use for such antibodies, and methods for using the antibodies to treat diseases associated with ganglioside GD2. In addition, tissue culture media supplements are described as are methods of use for the supplements. Described herein are albumin-ganglioside conjugates and corresponding methods for producing such conjugates. Methods of purifying or isolating antibodies are also described.
摘要翻译: 本文描述了特异性结合神经节苷脂GD2的抗体。 还描述了编码这种抗体的核苷酸,表达这种抗体的细胞,这种抗体的使用方法,以及使用该抗体治疗与神经节苷脂GD2相关的疾病的方法。 此外,组织培养基补充剂被描述为补充剂的使用方法。 本文描述的是白蛋白 - 神经节苷脂缀合物和用于产生这种缀合物的相应方法。 还描述了纯化或分离抗体的方法。
-
公开(公告)号:US20130305396A1
公开(公告)日:2013-11-14
申请号:US13876232
申请日:2011-09-28
申请人: Luigi Grasso , Jian Min Lin , Yuhong Zhou , Brian E. Tomkowicz , Nicholas C. Nicolaides , Philip M. Sass
发明人: Luigi Grasso , Jian Min Lin , Yuhong Zhou , Brian E. Tomkowicz , Nicholas C. Nicolaides , Philip M. Sass
IPC分类号: A61K49/00
CPC分类号: A61K49/0008 , A01K67/0278 , A01K2217/072 , A01K2227/105 , A01K2267/0331 , A01K2267/0368 , A01K2267/0375 , C07K14/7056 , C07K14/70596 , G01N33/5088
摘要: Provided herein are rodents that express the human endosialin gene. In preferred embodiments, the rodent is a mouse. Preferably, the human endosialin gene is integrated into the native or endogenous endosialin gene locus. More preferably, the host rodent is null for the endogenous endosialin gene product. The human endosialin gene is preferably expressed in a similar development and disease response pattern as that of the native endosialin gene product in parental or wild type rodents. This feature makes these rodents useful for studying the effects of test agents to positively or negatively affect endosialin biology for therapeutic use. Use of human endosialin expressing rodents lacking native endosialin gene product (HUE rodents) is proposed as a strategy for developing agents that can positively or negatively affect the endosialin pathway and also serve as a screening tool to identify those agents that may be useful as human therapies.
摘要翻译: 本文提供表达人内皮唾液酸基因的啮齿动物。 在优选的实施方案中,啮齿动物是小鼠。 优选地,人内皮唾液酸蛋白基因整合到天然或内源性内唾液酸基因座。 更优选地,宿主啮齿动物对于内源性内唾液酸基因产物是无效的。 人内皮唾液酸蛋白基因优选以与亲本或野生型啮齿动物中的天然唾液酸内切酶基因产物相似的发育和疾病应答模式表达。 该特征使得这些啮齿动物可用于研究试验剂对用于治疗用途的唾液酸生物学的正面或负面影响的影响。 提出缺乏天然唾液酸内切酶基因产物(HUE啮齿类动物)的人类内皮糖蛋白表达啮齿动物的使用作为可以对内皮唾液酸途径有正面或负面影响的发育剂的策略,也可作为鉴定可用作人类治疗的药物的筛选工具 。
-
公开(公告)号:US08507657B2
公开(公告)日:2013-08-13
申请号:US13593057
申请日:2012-08-23
CPC分类号: C07K16/3084 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/92
摘要: Described herein are antibodies that specifically bind ganglioside GD2. Also described are nucleotides encoding such antibodies, cells expressing such antibodies, methods of use for such antibodies, and methods for using the antibodies to treat diseases associated with ganglioside GD2. In addition, tissue culture media supplements are described as are methods of use for the supplements. Described herein are albumin-ganglioside conjugates and corresponding methods for producing such conjugates. Methods of purifying or isolating antibodies are also described.
摘要翻译: 本文描述了特异性结合神经节苷脂GD2的抗体。 还描述了编码这种抗体的核苷酸,表达这种抗体的细胞,这种抗体的使用方法,以及使用该抗体治疗与神经节苷脂GD2相关的疾病的方法。 此外,组织培养基补充剂被描述为补充剂的使用方法。 本文描述的是白蛋白 - 神经节苷脂缀合物和用于产生这种缀合物的相应方法。 还描述了纯化或分离抗体的方法。
-
公开(公告)号:US20120328524A1
公开(公告)日:2012-12-27
申请号:US13593057
申请日:2012-08-23
CPC分类号: C07K16/3084 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/92
摘要: Described herein are antibodies that specifically bind ganglioside GD2. Also described are nucleotides encoding such antibodies, cells expressing such antibodies, methods of use for such antibodies, and methods for using the antibodies to treat diseases associated with ganglioside GD2. In addition, tissue culture media supplements are described as are methods of use for the supplements. Described herein are albumin-ganglioside conjugates and corresponding methods for producing such conjugates. Methods of purifying or isolating antibodies are also described.
摘要翻译: 本文描述了特异性结合神经节苷脂GD2的抗体。 还描述了编码这种抗体的核苷酸,表达这种抗体的细胞,这种抗体的使用方法,以及使用该抗体治疗与神经节苷脂GD2相关的疾病的方法。 此外,组织培养基补充剂被描述为补充剂的使用方法。 本文描述的是白蛋白 - 神经节苷脂缀合物和用于产生这种缀合物的相应方法。 还描述了纯化或分离抗体的方法。
-
公开(公告)号:US07807382B2
公开(公告)日:2010-10-05
申请号:US12062630
申请日:2008-04-04
IPC分类号: G01N33/567 , G01N33/53
CPC分类号: C07K16/2851 , A61K47/6803 , A61K47/6849 , A61K2039/505 , C07K2317/14 , C07K2317/24 , C07K2317/56 , C07K2317/76 , C07K2319/30
摘要: The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods for identifying inhibitors of the interaction of endosialin with endosialin ligands. Also provided are methods for inhibiting angiogenesis and neovascularization in vivo and in vitro.
摘要翻译: 本发明提供了抑制内皮素与内皮素配体相互作用的方法。 通过抑制内皮素基因表达和蛋白质水平,通过阻断细胞表面表达的内皮唾液酸与诸如纤连蛋白和胶原的配体的相互作用来实现抑制。 本发明提供鉴定抑制剂的方法,所述抑制剂与内皮素配体相关。 还提供了用于在体内和体外抑制血管生成和新生血管形成的方法。
-
公开(公告)号:US07211254B2
公开(公告)日:2007-05-01
申请号:US10772437
申请日:2004-02-06
申请人: Kenneth J. Holroyd , Roy C. Levitt , W. Lee Maloy , Jamila Louahed , Mike McLane , Nicholas C. Nicolaides , Yuhong Zhou , Qu Dong
发明人: Kenneth J. Holroyd , Roy C. Levitt , W. Lee Maloy , Jamila Louahed , Mike McLane , Nicholas C. Nicolaides , Yuhong Zhou , Qu Dong
IPC分类号: A61K39/395
CPC分类号: C07K14/705 , A61K38/00 , G01N33/6872 , G01N2500/00 , Y10S977/914 , Y10S977/927
摘要: A new gene in the calcium-activated chloride channel family has been discovered that is induced by IL-9, thereby providing a therapeutic target in IL-9 mediated development of atopic allergy, asthma-related disorders and cystic fibrosis. A method for the identification and use of small molecule inhibitors of this gene and its products to treat these disorders has also been discovered. The invention also includes a method for diagnosing susceptibility to, and assessing treatment of atopic allergy, asthma-related disorders by measuring the level of gene expression in biologic samples using antibody specific for this protein.
摘要翻译: 已经发现钙激活的氯化物通道家族中的新基因被IL-9诱导,从而在IL-9介导的特应性过敏,哮喘相关病症和囊性纤维化的发展中提供治疗靶标。 还发现了用于鉴定和使用该基因的小分子抑制剂及其产物来治疗这些疾病的方法。 本发明还包括通过使用对该蛋白质特异的抗体来测量生物样品中基因表达的水平来诊断对特应性变态反应的哮喘相关疾病的易感性和评估治疗哮喘相关疾病的方法。
-
公开(公告)号:US07919248B2
公开(公告)日:2011-04-05
申请号:US12109780
申请日:2008-04-25
CPC分类号: C07K16/244 , A61K2039/505
摘要: The present invention is drawn to methods for modulating IL-13 expression and/or activity in a mammal comprising administering an effective amount of an agent which modulates the expression and/or activity of IL-9.
摘要翻译: 本发明涉及用于调节哺乳动物IL-13表达和/或活性的方法,其包括施用有效量的调节IL-9的表达和/或活性的药剂。
-
公开(公告)号:US20110033455A1
公开(公告)日:2011-02-10
申请号:US12873667
申请日:2010-09-01
IPC分类号: A61K39/395 , C12N5/071 , A61P35/00
CPC分类号: C07K16/2851 , A61K47/6803 , A61K47/6849 , A61K2039/505 , C07K2317/14 , C07K2317/24 , C07K2317/56 , C07K2317/76 , C07K2319/30
摘要: The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods for identifying inhibitors of the interaction of endosialin with endosialin ligands. Also provided are methods for inhibiting angiogenesis and neovascularization in vivo and in vitro.
摘要翻译: 本发明提供了抑制内皮素与内皮素配体相互作用的方法。 通过抑制内皮素基因表达和蛋白质水平,通过阻断细胞表面表达的内皮唾液酸与诸如纤连蛋白和胶原的配体的相互作用来实现抑制。 本发明提供鉴定抑制剂的方法,所述抑制剂与内皮素配体相关。 还提供了用于在体内和体外抑制血管生成和新生血管形成的方法。
-
公开(公告)号:US07504409B2
公开(公告)日:2009-03-17
申请号:US10838338
申请日:2004-05-05
申请人: Yuhong Zhou , Roy C. Levitt , Nicholas C. Nicolaides , Steve Jones , Mike McLane
发明人: Yuhong Zhou , Roy C. Levitt , Nicholas C. Nicolaides , Steve Jones , Mike McLane
IPC分类号: A01N43/54 , A61K31/517
CPC分类号: A61K9/122 , A61K31/192 , A61K31/195 , A61K31/443 , A61K31/47 , A61K31/5415 , A61K31/722 , A61K31/724
摘要: The claimed invention relates to methods of modulating mucin synthesis and the therapeutic application of compounds in controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases (COPD) including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infectious diseases.
-
-
-
-
-
-
-
-
-